 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Callisto's Cancer Drug Atiprimod to be Presented at Major Scientific Conference on AngiogenesisPress Release February 15, 2006 NEW YORK--(BUSINESS WIRE)--Feb 15, 2006 - Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that one of its scientists will be giving an invited presentation on its anti-cancer drug candidate, Atiprimod, at GTCbio, a major scientific conference in March in San Diego, CA. GTCbio is designed to highlight exciting new research and development of angiogenesis inhibitors and growth factors. At the conference, Dr. Kunwar Shailubhai, Senior Vice President of Discovery Research at Callisto Pharmaceuticals, Inc., will highlight the unique promise of Atiprimod, a potential anti-cancer treatment that is presently in a Phase I/IIa clinical trial in relapsed multiple myeloma patients. "Multiple myeloma continues to be a devastating cancer that is difficult to treat once patients relapse and become refractory to approved therapies," said Dr. Shailubhai. "We are continuing to explore Atiprimod's unique characteristics, including its anti-angiogenic activity as a potentially new drug alternative for cancer patients." The GTCbio conference will also feature speakers from many of the largest pharmaceutical companies in the world, including Pfizer, GlaxoSmithKline, Amgen, Eli Lilly & Co. and Bayer Pharmaceuticals. The conference is being held March 9-10, 2006, at Mariott's Old Town Courtyard in San Diego, California. Callisto has exclusive worldwide licenses from AnorMED Inc. and the M. D. Anderson Cancer Center, to develop, manufacture, use and sell Atiprimod. About GTCbio GTCbio produces conferences that facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. Our conferences focus on recent developments in biotechnology, status of emerging treatments, and research on future advances. GTCbio also provides staffing and placement assistance within the biotech sector, and consults on intellectual property awareness, evaluation and alliances. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002. For more information about the Angiogenesis Research & Therapeutics Conference, please visit: http://www.gtcbio.com/program.asp?cid=22. About Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in pre-clinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit http://www.callistopharma.com. Forward-Looking Statements Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing. Contact Callisto Pharmaceuticals, Inc. Dan D'Agostino, 212-297-0010 ext. 227 dagostino@callistopharma.com or Investor Relations Trilogy Capital Partners, Inc. Paul Karon, 800-592-6067 paul@trilogy-capital.com.
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page